CLIONIDINE AND THE SKELETAL MYOPATHY OF HEART FAILURE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目的1.确定使用另一种交感神经治疗药物可乐定的慢性治疗是否能逆转心力衰竭的骨骼肌病，并提高运动耐量。 1.1接受可乐定治疗的心力衰竭患者的MSNA慢性降低是否与骨骼肌病的逆转有关？ 1.2骨骼肌病的改善对心衰患者肌力感受器敏感性的增强有何影响？

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific Aim 1. To determine if chronic therapy with another sympatholytic therapy, clonidine, reverses the skeletal myopathy of HF, and increases exercise tolerance. 1.1 Is the chronic decrease in MSNA in HF patients treated with clonidine associated with a reversal of the skeletal myopathy? 1.2 What is the effect of the improved skeletal myopathy on the augmented muscle mechanoreceptor sensitivity in HF?